Member Info for Treadstone

Two page article by Simon Thompson in today's Investors Chronicle entirely devoted to MXC and its portfolio of holdings.. He recommends purchasing at 2.65p with a six months target of 3.75p. I have posted his comments on Castleton on Ctp board just now. Hopefully you can find it on the web or the mag in a newsagent. Cant face typing the whole thing out unfortunately....

Although not in this I notice it was tipped in todays Daily Telegraph as a speculative buy even after yesterdays strong rise. GLA

Sorry. I meant ...rarely get right. If I really get my entry timing right I would be well off which I 'm not unfortunately.

In a live interview several months back (involving answers to questions submitted by investors), John Watkins at the end stated that in mid april a trading update will be provided. I think its this that lies behind the rise. Bearing in mind funding for RM was done at a price of 331p the share price is well below that. At the time of the RM purchase there was much criticism about the price paid and negative views expressed regarding one of its subsidiaries. That sunk the sp for a while, but since its been some time since any update on trak's trading performance much is expected from the next one judging by past growth patterns. Though not in here, I quietly forgot about the april update and may jump in monday. P/e here is far too high but mr market does'nt seem to mind as long as strong growth continues.

Thanks. Should have read through the post more carefully, but there's still no info regarding ratio of institutions to private investors who took up the new shares. I was'nt contacted about any offer which is unusual, so maybe it was the institutions who bought the lions share. strange but I'll leave it at that. Will watch this as the market may over do the sp on the downside providing a better opportunity to buy in. Timing is something I really get right along with others I suspect. For there to be winners there has to be losers.

If you look at the 3 yr chart for the share price it went up from 2p to 12 p and ever since has been retreating. Its now down roughly 55% from the high. I'm not up on my Fibonnaci stuff but sometimes shares have been known to retreat up to 75%. TA is not my forte but as you say cash burn is a feature of this type of stock and that has'nt helped sentiment. Nevertheless this company does important research into cancers and has quality working partners to eventually bring solutions. I think I should have waited here for a better entry price but got caught up in a dead cat bounce that led me to think it might continue its upward trajectory. My fault entirely. Just one other question for you. According to what I can see there has been no RNS saying who underwrote the £8.1m placing and at what price. I certainly was'nt approached to participate so can you see anything about this..??

Bio stocks can be a difficult investment especially in a volatile market. They need to have an exciting drug such as those offered by opti or mtfb which should do well in the market place. Investors who got in early in either of those two will have done very well. At some point in the future the tie up with novartis may pay off but the market does'nt have the patience to wait and see at the moment. Nevertheless sentiment may turn around depending on the 28/4 Rns.

Decided to sell this morning with a 40% loss. A number of small pharma research stocks being sold off for some reason. Oxp not short of funds but market impatient for a deal and not sure if/when it may happen. I'll have to take the loss on the chin. This is more of a traders market than a holders in my opinion.

Sold out first thing this morning as this is starting to fall back seriously. The market either knows or suspects something is'nt quite right here. Just shows that this is a traders and not a holders market . Should have bought this with a stop loss in mind.

I don't entirely understand the reason for the fall other than the feeling no news is forthcoming apart from the figures on the 28th April and maybe the market believes they might not be good. Not a brilliant buy at 8.50p by me. Thought this would do better.

raised £8.1m in february from institutional investors at 6.3p which obviously dragged the sp down. Financial figures will be out on 28th April so only a month away. Maybe there'll be a forward looking statement included regarding any manufacturing deals with Novartis. We'll see.

has a buy out on this today and the sp retreats. So much for candlestick TA. Need some news with meat on the bone to move this share into a higher trading range. For the moment it seems stuck.

I got in here at 6.50p thinking it was half way from the top of 13p and looked interesting. In a risky volatile market I thought this type of stock was less likely to suffer than others. I put in about £5k so not too much and similar in OXB only to see a 30% drop in both. I don't know what to make of prospects here as we're all in the dark. Supposedly we are in discussions with possible partners to bring a new ibuprufen to market and a new director appointedto help bring this about. The company has other developments but this is the main driver. The problem with this type of business is that developing new drugs eats a lot of capital upfront and losses are inevitable until they hopefully reach the market. Oxp does'nt manufacture and needs a partner to do that, and presumably derives an income from future sales. There is a vast prospective market for ibuprufen out there already, but since the Boots patent expired long ago its now very cheap to buy. So for the new oxp ibuprufen any partnership negotiation will involve competitive pricing and the selling points that will attract customers to buy the new product instead of the current one. One assumes this was worked out by oxp before they went full out on this, so it should look attractive to big pharma otherwise why bother. In other words the sums should add up. Apart from that its a matter of waiting to see the outcome and that could take a while. As for the share price it has fallen quite low and moving sideways waiting for news. I had high hopes myself but the share market is incredibly volatile and most of my shares are down. I often wonder whether its risky to hold longer or not.

2 trades with no volume traded. How does that work ??

Todays Rns re deal with Alibaba may have been rumoured a while back kick starting the move up from the lows. Not in this but looks positive for the company.

Agree with your point of view, but I've come to the conclusion that it will take longer for any partnership deals to be concluded than I originally thought. Nobody has got excited by todays news by the look of it either so probably others agree as well. Todays company statements are just repeats of ones made earlier ie we're searching for partners to bring the ibuprufen and Naproxin products to market. The prospective market is huge but very competitive with Ibuprufen prices very low now that generics have long been on the shelves. To me this means pricing must be a key issue here. What we do have is £20m in the bank, and that will give Oxp the ammunition to fund a long campaign to find a jv partner. So in that sense we're ok. We just need a result. Patience required......

one just does'nt stop climbing. used to be in this when it was trading in the seventies. don't entirely understand what's behind it.

Well I'm hoping for some news by Easter on this one particularly on the partnership discussions. I assume the on going negotiations are the main reason for the silence.

If Aviva plc and its subsidiaries have increased their holding there has to be a good reason for doing so. Being a tier one institutional investor I'm sure Aviva have a better idea than me on this stock so I'll follow them. In the last market selloff the share price did'nt drop by much either which is a good sign because more panics are likely for reasons we all know.

Looks like someone is accumulating stock and sp trying to move up a little. Have kept my small holding here and will see how things progress.